Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL35P6 (ribosomal protein L35 pseudogene 6) is a human pseudogene related to the ribosomal protein L35 gene[2][4]. Unlike the active RPL35 gene, which encodes a structural ribosomal protein essential for protein synthesis[1][3][8][9], RPL35P6 does not produce a functional protein and has no known molecular function. Pseudogenes such as RPL35P6 are generally remnants of gene duplications or retrotranspositions and may be annotated for genomic studies but are not considered therapeutic targets, receptors, enzymes, or relevant for drug development. Any therapeutic or disease associations attributed to RPL35P6 would be incorrect and likely the result of misidentification or annotation errors; only the protein-coding RPL35 should be considered in functional or disease contexts. In summary: RPL35P6 is a pseudogene, not an active drug target, receptor, or enzyme. Queries treating it as a therapeutic target are likely incorrect and should be redirected to RPL35, the protein-coding gene[2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L35 pseudogene 6 (RPL35P6).